2 results
Approved WMOCompleted
To determine the antileukemic activity of combination chemotherapy including bortezomib as reinduction therapy in childhood relapsed/refractory ALL.
Approved WMORecruiting
Primary objectives: Improvement of CR2 rates after induction with ALL R3 with bortezomib versus withoutbortezomib in HR relapsed ALL patientsSecondary objectives:Improvement of Event Free Survival (EFS) and overall survival (OS) ratesImprovement of…